MPG.eBooks - Description: Alpha1-proteinase inhibitors for the treatment of alpha1-antitrypsin deficiency

Cover Image

Read Now

Alpha1-proteinase inhibitors for the treatment of alpha1-antitrypsin deficiency a review of clinical effectiveness, cost-effectiveness, and guidelines

This report will focus on the clinical effectiveness, cost-effectiveness and evidence based guidelines for the use of alpha1-antitrypsin (AAT) augmentation therapy in adult patients with AAT deficiency, regardless of baseline lung function

Bibliographic Details
Main Authors:	Reynen, Emily, Visintini, Sarah (Author)
Format:	eBook
Language:	English
Published:	Ottawa Canadian Agency for Drugs and Technologies in Health 2017, December 21, 2017
Edition:	Version 1.0
Series:	CADTH rapid response report: summary with critical appraisal
Subjects:	Comparative Effectiveness Research Cost-benefit Analysis Alpha 1-antitrypsin Deficiency / Drug Therapy Lung Diseases / Drug Therapy Alpha 1-antitrypsin / Therapeutic Use Practice Guidelines As Topic
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK526295
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	This report will focus on the clinical effectiveness, cost-effectiveness and evidence based guidelines for the use of alpha1-antitrypsin (AAT) augmentation therapy in adult patients with AAT deficiency, regardless of baseline lung function
Physical Description:	1 PDF file (26 pages) illustration